Home Journals Articles Updates About
CN
image
收藏切换
Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy
收藏切换
Acta Pharmaceutica Sinica B | 2025, 15(12) : 6510 - 6528
Less
收藏切换
Acta Pharmaceutica Sinica B | 2025, 15(12): 6510-6528
• Original articles •
Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy
Full
Affiliations
Published: 2025-12-25 doi: 10.1016/j.apsb.2025.09.009
Outline
收藏切换
Degrader–antibody conjugates (DACs) represent a promising drug modality for targeting hematological malignancy, but still lack rational design frameworks. Here, we show the strategies of reasonable antibody-degrader compatibility and degradation tail-derived conjugatability through a systematic exploration. Inspired by the success of IKZF1/3 degraders, we sought to explore the potential of cereblon E3 ligase modulators (CELMoDs) in constructing novel conjugates. By combining a modular library with neo-substrate screening and further conjugatable derivation, I034 was identified, a potent CELMoD payload with picomolar degradation activity and antiproliferative effects. Through linker chemistry, I034-based DACs were constructed and demonstrated superior efficacy and safety compared to auristatin-based conjugates both in vitro and in vivo, with the CD38-targeting Dara-VA-I034 achieving complete tumor eradication at low doses. Mechanistic insights revealed distinct positive feedback regulation of CD38 conjugates, highlighting the need for compatibility between payloads and antigens. These results demonstrate that the approach could provide a framework for discovering CELMoD payloads and advancing DACs for treating multiple myeloma and other malignancies.
Degrader-antibody conjugate  /  Antibody-drug conjugate  /  Cereblon E3 ligase modulator  /  Immunomodulatory drug  /  Molecular glue  /  Targeted protein degradation  /  Multiple myeloma  /  Hematologic malignancy
. Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy. 药学学报（英文版）, 2025 , 15 (12) : 6510 -6528 . DOI: 10.1016/j.apsb.2025.09.009
. Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy[J]. Acta Pharmaceutica Sinica B, 2025 , 15 (12) : 6510 -6528 . DOI: 10.1016/j.apsb.2025.09.009
Appendix
Less
Year 2025 volume 15 Issue 12
29
0
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.apsb.2025.09.009
  • Receive Date：2025-02-14
  • Online Date：2026-10-25
  • Published：2025-12-25
Article Data
Affiliations
History
  • Received：2025-02-14
  • Revised：2025-06-05
Funding
Affiliations
References
Share
https://castjournals.cast.org.cn/joweb/apsb/EN/10.1016/j.apsb.2025.09.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House